Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
2.330
-0.050 (-2.10%)
At close: Jun 10, 2025, 4:00 PM
2.360
+0.030 (1.29%)
After-hours: Jun 10, 2025, 6:57 PM EDT
Savara Employees
Savara had 59 employees as of December 31, 2024. The number of employees increased by 22 or 59.46% compared to the previous year.
Employees
59
Change (1Y)
22
Growth (1Y)
59.46%
Revenue / Employee
n/a
Profits / Employee
-$1,731,763
Market Cap
490.91M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
SVRA News
- 13 days ago - Savara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation - Accesswire
- 14 days ago - Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday? - Benzinga
- 14 days ago - BREAKING: Savara Shares Down Over 30%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses - GlobeNewsWire
- 14 days ago - Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) - Business Wire
- 18 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 19 days ago - Savara Announces Participation in Jefferies Global Healthcare Conference - Business Wire
- 23 days ago - Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 - Business Wire
- 4 weeks ago - Savara Reports First Quarter 2025 Financial Results and Provides a Business Update - Business Wire